Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multinationals Eye Divesting Established Products In China Amid Fierce Competition, Shifting Focus

Executive Summary

Farewell established products, hello innovative new drugs! As pricing pressures mount, more multinational companies including Lilly and Roche are switching their business focus in China, looking at product divestments and partnering with local firms.

You may also be interested in...



Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

Drug Price Waterloo: China's New Bidding Process Hits MNCs Hard

China's new so-called “4+7” drug bidding pilot scheme, already expected to be a killer for some companies, has cut prices by as much as 90%, leaving all but two multinationals to bid successfully and accept the revised levels. The big reductions could also lead to further price erosion for the winning products.

Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124214

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel